Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07261150 · ClinicalTrials.gov registry record · Phase 3
Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT)
A Phase 3 study, sponsored by University of Minnesota.
- Not yet
- Registry status
- Phase 3
- Development phase
- 664
- Enrollment target
NCT07261150 is a Phase 3 study that has not yet begun recruiting, run by University of Minnesota. The registered enrollment target is 664 participants.
The verdict
NCT07261150, a Phase 3 study, has not yet begun recruiting, sponsored by University of Minnesota.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 664 participants
- Enrollment target
Study Summary
The purpose of the study is threefold: 1. Assess the safety and efficacy of a single high-dose intravenous (LAmB 10mg/kg) compared to the SOC daily dosing (3mg/kg) of the same medication for induction therapy in moderate to severe histoplasmosis. 2. Assess the safety and efficacy of oral posaconazole 300mg delayed-release tablets three times daily for two days then once daily for consolidation therapy compared to SOC oral itraconazole 200 mg capsules three times daily for three days then twice daily in moderate to severe histoplasmosis 3. Assess the safety and efficacy of 6 months of consolidation therapy compared to the SOC 12 months of consolidation therapy in persons with HIV on appropriate antiretroviral therapy.
Interventions
- DRUG Posaconazole
- DRUG LAmB B
- DRUG World Health Organization (WHO)-recommended SOC
- DRUG WHO-recommended SOC Itraconazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 664 participants |
| Start Date | 2026-09-15 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07261150
The ClinicalTrials.gov registry entry for NCT07261150 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 664 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Posaconazole is the first listed.
NCT07261150 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07261150 about?
NCT07261150 is a clinical study titled "Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT)". The purpose of the study is threefold: 1. Assess the safety and efficacy of a single high-dose intravenous (LAmB 10mg/kg) compared to the SOC daily dosing (3mg/kg) of the same medication for induction therapy in moderate to severe histoplasmosis. 2. Assess the safety and efficacy of oral posaconazo...
What is the current status of trial NCT07261150?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 664 participants. The study started on 2026-09-15. Estimated completion is 2030-12-31.
What interventions are being tested in trial NCT07261150?
The interventions under investigation include: Posaconazole (DRUG), LAmB B (DRUG), World Health Organization (WHO)-recommended SOC (DRUG), WHO-recommended SOC Itraconazole (DRUG).
Who is sponsoring clinical trial NCT07261150?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.